New tests launched in September
In September 2022, Mayo Clinic Laboratories announced ten new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
The new tests that launched in September 2022 by Mayo Clinic Laboratories:
This test is intended for detecting and identifying bacteria (including mycobacteria) from normally sterile sources, including synovial fluid; body fluids such as pleural, peritoneal, and pericardial fluids, cerebrospinal fluid; and both fresh and formalin-fixed paraffin-embedded tissues.
This test is intended for diagnosing hereditary angioedema, and monitoring response to C1 esterase inhibitor replacement therapy.
This test is intended for free and weakly bound testosterone (FWBT), also referred to as bioavailable testosterone, is thought to reflect an individual's biologically active, circulating testosterone.
FLACQ | Lactoferrin, Quantitative, Stool
This test is intended for Virologic detection and confirmation of hepatitis E virus (HEV) infection in individuals who are immunocompromised and are at risk for or suspected to have acute or chronic hepatitis E.
This test is intended for aiding in the diagnosis and carrier detection of KLF1 sequence alterations that are reported to be responsible for neonatal anemia or jaundice, hydrops fetalis, increased fetal hemoglobin and hemoglobin A2.
This test is intended for the detection of non-variola Orthopoxvirus in individuals presenting with signs and symptoms suggestive of monkeypox.
This test is intended for monitoring patients with maple-syrup urine disease using specimens collected at home.
This test is intended for verifying abstinence or use of ethanol especially in liver transplant candidates/patients
In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories: